Kalaris Therapeutics, Inc.
KLRSNasdaq
$4.38
↓ -5.0%Jul 17 close · end-of-day
Price
1Y↑ +78.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$103.9M
Enterprise Value
$6.7M
P/E
—
P/S
—
P/B
1.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$44.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-64.3%
ROIC
—
Debt / Equity
—
Net Cash
$97.2M
Return 1Y
+81.0%
Company profile
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies. The company's lead product is posoleucel, which is an allogenic off the shelf VST therapy. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19.
- CEO
- Diana M. Brainard
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 110
- Headquarters
- Massachusetts
- Website
- allovir.com
Earnings
KLRS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.46↓ -81.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$71.3M | -$169.8M | -$171.2M | -$199.9M | -$51.7M | -$46.2M |
| Net income | -$69.8M | -$172.0M | -$168.7M | -$190.4M | -$69.2M | -$43.4M |
| Diluted EPS | — | -$2.74 | -$2.20 | -$42.09 | -$51.77 | -$2.85 |
| Operating cash flow | -$60.8M | -$106.3M | -$142.1M | -$124.5M | -$20.7M | -$38.4M |
| Free cash flow | -$61.0M | -$106.3M | — | — | — | -$38.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$4.2M | -$37.8M | -$7.1M | -$10.4M | -$12.3M | -$12.7M | -$10.8M | -$11.8M |
| Net income | -$5.7M | -$38.1M | -$22.0M | -$10.2M | -$11.3M | -$11.9M | -$10.0M | -$10.9M |
| Diluted EPS | -$4.26 | -$28.16 | -$16.75 | -$2.52 | -$0.61 | -$0.64 | $0.92 | -$0.46 |
| Operating cash flow | -$4.0M | -$4.3M | -$7.9M | -$7.4M | -$12.5M | -$11.3M | -$7.1M | -$11.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 20, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-20 | AKKARAJU SRINIVAS | Buy | 244,300 | $4.83 | $1.2M | filing |
| 2026-05-20 | AKKARAJU SRINIVAS | J | 66,906 | $0.00 | $0.00 | filing |
| 2026-05-20 | AKKARAJU SRINIVAS | J | 14,937 | $0.00 | $0.00 | filing |
| 2026-05-20 | AKKARAJU SRINIVAS | J | 4,471 | $0.00 | $0.00 | filing |
| 2026-03-20 | Hagen Brett R· Chief Accounting Officer | Sale | 1,915 | $6.72 | $12,868.80 | filing |
| 2025-12-22 | AKKARAJU SRINIVAS | Award | 1,500,000 | $10.00 | $15.0M | filing |
| 2025-12-18 | AKKARAJU SRINIVAS | Buy | 479,847 | $10.42 | $5.0M | filing |
Latest 7 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.